NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02334787,A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects,https://clinicaltrials.gov/study/NCT02334787,,COMPLETED,"To assess the safety (especially skin findings) and pharmacokinetics by applying 0.3%, 1%, or 3% formulation of 5g OPA-15406 ointment to a 1000 cm2 area as a single-dose and as a multiple-dose twice daily for 2 weeks in Japanese healthy adult male subjects.",YES,Atopic Dermatitis,DRUG: 0.3% OPA-15406 Ointment|DRUG: 1% OPA-15406 Ointment|DRUG: 3% OPA-15406 Ointment|DRUG: Placebo Ointment,"Cmax of OPA-15406 in a Single Administration Period, We measure the plasma concentration of OPA-15406 at Day 1 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as a single dose. We assess the Cmax of OPA-15406., Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hr|Cmax of OPA-15406 in the Multiple Administration Period, We measure the plasma concentration of OPA-15406 from Day 1 to Day 14 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as multiple doses twice daily for 2 weeks. We assess the AUC12h x of OPA-15406., Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hrs at Day 14","AUC12h of OPA-15406 in a Single Administration Period, We measure the plasma concentration of OPA-15406 at Day 1 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as a single dose. We assess the AUC12h x of OPA-15406., Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hrs|AUC12h of OPA-15406 in the Multiple Administration Period, We measure the plasma concentration of OPA-15406 from Day 1 to Day 14 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as multiple doses twice daily for 2 weeks. We assess the AUC12h x of OPA-15406., Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hrs at Day 14",,"Otsuka Pharmaceutical Co., Ltd.",,MALE,ADULT,PHASE1,32,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",271-14-001,2015-01,2015-02,2015-02,2015-01-08,2016-06-07,2016-10-03,"Kanto Region, Japan",
